7-OH withdrawal symptoms

7-OH (7-hydroxymitragynine) withdrawal is opioid withdrawal. Because 7-OH binds and activates mu-opioid receptors, stopping regular use produces the same physiological response as stopping any opioid: anxiety, muscle aches, sweating, nausea, diarrhea, insomnia, and strong cravings, typically beginning 6 to 12 hours after the last dose. Symptoms peak in the first one to three days and physically resolve for most people within a week, though mood, sleep, and cravings can persist for weeks.

At a glance: 7-OH withdrawal

QuestionAnswer
Does 7-OH cause withdrawal?Yes; 7-OH is a potent opioid-acting compound and stopping regular use produces opioid-type withdrawal
Most common symptomsAnxiety, muscle aches, sweating, nausea, diarrhea, insomnia, runny nose, yawning, and strong cravings
When do symptoms start?Usually 6 to 12 hours after the last dose
When do they peak?Days 1 to 3
How long does it last?Acute symptoms ease within about 5 to 7 days; mood, sleep, and cravings can linger for weeks
Is it dangerous?Rarely life-threatening, but dehydration and high relapse risk are real — medical support makes it safer and more manageable

Key Takeaways

  • 7-OH withdrawal is opioid withdrawal. 7-Hydroxymitragynine acts on the same mu-opioid receptors as morphine and oxycodone. Stopping produces the same flu-like, deeply uncomfortable symptoms.
  • Symptoms usually start within 6 to 12 hours and peak in the first one to three days. Most acute physical symptoms ease within a week. Low mood, sleep disruption, and cravings can persist longer.
  • Concentrated 7-OH products cause more intense withdrawal than kratom leaf. The higher potency of commercial extract products drives deeper physical dependence, which means a harder withdrawal when stopping.
  • The DEA's move to schedule 7-OH in July 2026 is pushing many daily users to stop, often abruptly. Abrupt cessation is the hardest version. A planned, medically supported quit is substantially more manageable.
  • You do not have to manage this alone. Buprenorphine (Suboxone) targets the same receptors driving withdrawal and can dramatically reduce symptoms and cravings. Treatment is available through telehealth in most states.

7-OH withdrawal symptoms: the full list

Physical symptoms

  • Muscle and joint aches, often deep and widespread
  • Sweating, alternating with chills and goosebumps
  • Runny nose and watery eyes
  • Yawning
  • Nausea, stomach cramping, and diarrhea
  • Vomiting in more severe cases
  • Restless legs, particularly at night
  • Disrupted sleep or complete insomnia
  • Rapid heart rate
  • Dilated pupils
  • Tremor or shaking

Psychological symptoms

  • Anxiety, often significant and without a specific focus
  • Irritability and agitation
  • Restlessness; difficulty staying still
  • Low mood or depressed affect
  • Difficulty concentrating
  • Intense cravings for 7-OH

Plain-language summary: 7-OH withdrawal symptoms are opioid-like and typically include anxiety, muscle aches, sweating, nausea, diarrhea, insomnia, and strong cravings, usually beginning 6 to 12 hours after the last dose.

Severity varies significantly based on product potency, daily dose, duration of use, frequency of dosing, and individual factors including metabolism and co-occurring health conditions.

7-OH withdrawal timeline: day by day

StageTimingWhat to expect
Onset6 to 12 hours after last doseEarly anxiety, cravings, runny nose, yawning, sweating, mild restlessness
PeakDays 1 to 3Most intense phase: GI distress, severe muscle aches, insomnia, restless legs, chills and sweating, strong cravings
EasingDays 4 to 7Physical symptoms gradually subside; sleep begins to improve; cravings often persist and can intensify as physical symptoms fade
Post-acute (PAWS)Weeks afterLingering low mood, sleep disruption, and intermittent cravings for some people

This is a general pattern, not a guarantee. Concentrated 7-OH products and heavy long-term use can produce a harder and longer withdrawal than this table suggests. Some people who were using very high-potency commercial products multiple times daily experience withdrawal more like moderate opioid withdrawal, with onset beginning even earlier and a longer acute phase.

How long does 7-OH withdrawal last?

For most people, the acute physical symptoms of 7-OH withdrawal ease significantly within 5 to 7 days. The post-acute phase — lower-grade mood disruption, sleep difficulty, and intermittent cravings — can persist for two to four weeks and sometimes longer. The longer and heavier the use, and the more potent the product, the longer the overall withdrawal arc tends to run.

Why 7-OH withdrawal can be worse than kratom leaf withdrawal

People who have used both kratom leaf powder and concentrated 7-OH products describe a meaningful difference in what stopping each one feels like. The reasons are pharmacological.

The concentration factor. Natural kratom leaf contains 7-OH at trace concentrations of 0.003% to 0.04% by dry weight. Commercial 7-OH products deliver 7-OH at 22 to 75 milligrams per gram, concentrations achievable only through chemical synthesis. Higher-potency receptor activation drives deeper neuroadaptation, and deeper neuroadaptation means a larger physiological gap when the product is stopped — and more severe withdrawal.

The onset factor. Because concentrated 7-OH products are dosed multiple times daily and clear the body in 5 to 8 hours, the dosing cycle is tighter and the mini-withdrawal between doses more acute. This tight cycle accelerates the development of physical dependence and sharpens the contrast when use stops.

The adulteration wildcard. Unregulated commercial 7-OH products have inconsistent actual potency regardless of the label, and FDA testing has documented commercial kratom products containing undeclared pharmaceutical drugs. Withdrawal from an adulterated product may be unpredictable in ways that reflect the unknown contents rather than 7-OH alone.

The ban factor. The DEA's July 2026 notices of intent to temporarily schedule concentrated 7-OH are driving many daily users to stop, often suddenly when products leave shelves. Abrupt discontinuation after heavy use produces the most severe version of withdrawal. A planned, medically supported transition substantially reduces what the person has to endure.

How to manage 7-OH withdrawal

This section covers general approaches. This is not medical advice. Talk to a clinician about what is appropriate for your specific situation.

At-home supportive measures

For milder withdrawal from less heavy use, these measures reduce discomfort:

  • Hydration and electrolytes. Diarrhea and sweating cause significant fluid loss. Water and electrolyte drinks help prevent dehydration.
  • Rest. Sleep will be difficult, but rest when possible.
  • Warmth. A heating pad or warm blanket helps with the chills and muscle aches.
  • Light food. Nausea reduces appetite, but eating what you can manage supports your body through the process.
  • Support from others. Having someone present during the peak days (days 1 to 3) matters — both for safety and because the relapse pull is strongest when you are alone and at peak discomfort.

These measures are appropriate for milder cases. For people with significant daily 7-OH dependence from concentrated products, supportive measures alone are often insufficient to manage the acute phase.

The medical path: buprenorphine

Buprenorphine (Suboxone) is the evidence-based treatment for 7-OH and kratom dependence. It works by stabilizing the same mu-opioid receptors that 7-OH was activating, which largely prevents the acute withdrawal phase rather than reducing it after the fact.

When started at the correct time in the withdrawal window, buprenorphine typically produces significant relief within one to two hours of the first dose. The deep muscle aches, restless legs, GI symptoms, and anxiety that define the peak largely do not occur. Post-acute symptoms are also shorter and milder.

The 2026 AIM Clinical Cases paper by Barrett et al. in Annals of Internal Medicine recommends buprenorphine as the preferred treatment for 7-OH and kratom dependence. Case series data show most people who start buprenorphine treatment remain in care for months and test negative for kratom alkaloids within 8 to 12 weeks.

One critical caution: buprenorphine must be started at the right time — after withdrawal has clearly begun — to avoid precipitated withdrawal. Starting too early while 7-OH is still significantly active on receptors causes buprenorphine to displace 7-OH and produce a sudden, severe symptom crash. A prescriber times the first dose using the COWS scale to assess your withdrawal level. This is not a step to manage without clinical guidance.

For the full mechanism explanation, see Does Suboxone Block 7-OH?

When to seek help promptly

  • You cannot keep fluids down or are becoming dehydrated
  • Symptoms feel medically serious rather than just deeply uncomfortable
  • You are also using alcohol, benzodiazepines, or other substances alongside 7-OH
  • Severe depression or thoughts of self-harm are present
  • You have tried to stop before and have not been able to get through the peak

For any of these, contact a clinician rather than attempting to manage alone. Telehealth providers can assess you by video in most states, often the same day.

SAMHSA's free helpline (1-800-662-4357) is available 24/7 and can connect you to local resources.

Frequently Asked Questions

How long does 7-OH withdrawal last?

The acute phase of 7-OH withdrawal typically lasts 5 to 7 days for most people, with the worst symptoms in the first one to three days. A post-acute phase with lower-grade mood disruption, sleep difficulty, and intermittent cravings can persist for two to four weeks or longer with heavy long-term use. Concentrated product use generally produces a longer and harder withdrawal than kratom leaf.

Is 7-OH withdrawal dangerous?

7-OH withdrawal is not typically life-threatening in the way alcohol or benzodiazepine withdrawal can be, which carry risk of seizures and cardiovascular events. However, severe vomiting and diarrhea can cause dehydration and electrolyte imbalances that warrant medical attention. The relapse risk during the peak is also clinically significant: using 7-OH brings almost immediate relief from every symptom, which is why the peak days carry such high return-to-use rates without support.

What helps with 7-OH withdrawal?

For mild cases: hydration, electrolytes, rest, and support from others. For moderate to severe cases, particularly with concentrated 7-OH products: buprenorphine (Suboxone), which stabilizes the mu-opioid receptors driving withdrawal and largely prevents the acute phase when started at the right time under prescriber guidance. Attempting unsupported cold turkey from significant 7-OH dependence has a high failure rate.

Is 7-OH the same as kratom?

Not exactly. Kratom is the plant. 7-OH (7-hydroxymitragynine) is a minor alkaloid in the kratom plant that is concentrated or synthesized to produce commercial 7-OH products. Natural kratom leaf contains 7-OH at trace levels; commercial products deliver it at concentrations achievable only through chemical processing. 7-OH is substantially more potent at opioid receptors than mitragynine, the primary alkaloid in kratom leaf, which is why 7-OH withdrawal tends to be more severe than kratom leaf withdrawal.

Does 7-OH cause withdrawal?

Yes. 7-OH produces opioid-type physical dependence because it activates mu-opioid receptors in the same way classical opioids do. Regular use causes neuroadaptation; stopping causes the adapted system to go into deficit. The withdrawal syndrome is pharmacologically identical to opioid withdrawal from other substances, and it follows the same general timeline and symptom profile.

Ready to manage this with medical support?

Telehealth evaluations are available in most states, often the same day. Your provider guides the induction timing and first dose.

SAMHSA's free helpline: 1-800-662-4357, available 24/7. This article is for educational purposes only and is not medical advice. Symptoms and timelines vary — talk to a clinician about your specific situation before making decisions about stopping 7-OH or starting any medication.

Next Steps

Sources

  1. U.S. Food and Drug Administration. 7-Hydroxymitragynine (7-OH): An Assessment of the Scientific Data and Toxicological Concerns Around an Emerging Opioid Threat. FDA; July 2025. https://www.fda.gov/files/drugs/published/7-hydroxymitragynin_7-oh_an_assessment_of_the_scientific_data_and_toxicological_concerns_around_an_emerging_opioid_threat.pdf
  2. Drug Enforcement Administration. Schedules of Controlled Substance: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I. Federal Register. Published July 6, 2026. Document No. 2026-13580. https://www.federalregister.gov/documents/2026/07/06/2026-13580/schedules-of-controlled-substance-temporary-placement-of-7-hydroxymitragynine-above-a-specified
  3. Wightman RS, et al. A Case of 7-OH Mitragynine Use Requiring Inpatient Medically Managed Withdrawal. Journal of Addiction Medicine. Published online August 4, 2025. doi:10.1097/ADM.0000000000001558. https://pubmed.ncbi.nlm.nih.gov/40758956/
  4. Barrett E, Hendy L, Lira MC, et al. What Clinicians Should Know About Kratom and 7-OH Mitragynine. AIM Clinical Cases (Annals of Internal Medicine: Clinical Cases). 2026;5:e251249. doi:10.7326/aimcc.2025.1249. https://www.acpjournals.org/doi/10.7326/aimcc.2025.1249
  5. Management of acute withdrawal from 7-hydroxymitragynine after high-dose chronic use: a case report. American Journal of Health-System Pharmacy. 2026. https://www.sciencedirect.com/science/article/pii/S1544319126000324
  6. Brown J, et al. Elevated 7-Hydroxymitragynine Levels Found in Products Misbranded as Kratom. Journal of Analytical Toxicology. 2025. PMID: 41065466. https://pubmed.ncbi.nlm.nih.gov/41065466/
  7. Substance Abuse and Mental Health Services Administration. TIP 63: Medications for Opioid Use Disorder. Publication No. PEP21-02-01-002. SAMHSA; 2021. https://library.samhsa.gov/product/tip-63-medications-opioid-use-disorder-executive-summary/pep21-02-01-003
  8. American Society of Addiction Medicine. The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. ASAM; 2020.
This article is for educational purposes only and is not a substitute for professional medical advice. If you are experiencing severe withdrawal symptoms, contact a healthcare provider or go to your nearest emergency room.